Mohd Ali Faiz, C. H. Ding, A. Wahab, M. N. Tzar, A. Sulong, K. Wong, P. F. Wong
Background: Pseudomonas aeruginosa is a notorious gram-negative bacterium that has become a globalpublic health concern owing to the emergence of multi- and pandrug-resistant strains. This study sought todetermine the antibiotic susceptibility profile of P. aeruginosa in a tertiary medical center from Malaysia. Materials and Methods: Each isolate’s identity was confirmed using the VITEK 2 GN kit, and subjectedto antibiotic susceptibility testing using the VITEK 2 AST-N374 card (for testing against piperacillintazobactam,ceftazidime, cefepime, imipenem, meropenem, amikacin, gentamicin and ciprofloxacin) andEtest strips (for testing against doripenem and polymyxin B). Isolates which were not susceptible to >1carbapenem were tested for carbapenemase production using the modified carbapenem inactivationMethod (mCIM). Results: Out of 102 isolates studied, 64 (62.7%) were fully susceptible to all the antibiotics tested.Twenty-six (25.5%) were resistant to >1 antibiotic from >2 antibiotic classes, and 21 (20.6%) wereresistant to >1 antibiotic from >3 classes. Susceptibility was highest with polymyxin B (100%) and lowestwith piperacillin-tazobactam (64.7%). Carbapenem susceptibility was between 78.4% to 81.4%. Out of 22isolates which were not susceptible to >1 carbapenem, 18 (81.8%) were not susceptible to all threecarbapenems. Conclusion: More than half of our P. aeruginosa isolates were fully susceptible to all the anti-pseudomonalantibiotics tested. Multidrug-resistant strains accounted for between 20% to 25% of all our P. aeruginosaisolates. Through mCIM testing, carbapenemase production did not appear to be the dominant resistancemechanism. J MEDICINE 2022; 23: 54-60
{"title":"The Antibiotic Resistance Profile of Pseudomonas Aeruginosa in a Tertiary Medical Center from Malaysia","authors":"Mohd Ali Faiz, C. H. Ding, A. Wahab, M. N. Tzar, A. Sulong, K. Wong, P. F. Wong","doi":"10.3329/jom.v23i1.57938","DOIUrl":"https://doi.org/10.3329/jom.v23i1.57938","url":null,"abstract":"Background: Pseudomonas aeruginosa is a notorious gram-negative bacterium that has become a globalpublic health concern owing to the emergence of multi- and pandrug-resistant strains. This study sought todetermine the antibiotic susceptibility profile of P. aeruginosa in a tertiary medical center from Malaysia.\u0000Materials and Methods: Each isolate’s identity was confirmed using the VITEK 2 GN kit, and subjectedto antibiotic susceptibility testing using the VITEK 2 AST-N374 card (for testing against piperacillintazobactam,ceftazidime, cefepime, imipenem, meropenem, amikacin, gentamicin and ciprofloxacin) andEtest strips (for testing against doripenem and polymyxin B). Isolates which were not susceptible to >1carbapenem were tested for carbapenemase production using the modified carbapenem inactivationMethod (mCIM).\u0000Results: Out of 102 isolates studied, 64 (62.7%) were fully susceptible to all the antibiotics tested.Twenty-six (25.5%) were resistant to >1 antibiotic from >2 antibiotic classes, and 21 (20.6%) wereresistant to >1 antibiotic from >3 classes. Susceptibility was highest with polymyxin B (100%) and lowestwith piperacillin-tazobactam (64.7%). Carbapenem susceptibility was between 78.4% to 81.4%. Out of 22isolates which were not susceptible to >1 carbapenem, 18 (81.8%) were not susceptible to all threecarbapenems.\u0000Conclusion: More than half of our P. aeruginosa isolates were fully susceptible to all the anti-pseudomonalantibiotics tested. Multidrug-resistant strains accounted for between 20% to 25% of all our P. aeruginosaisolates. Through mCIM testing, carbapenemase production did not appear to be the dominant resistancemechanism.\u0000J MEDICINE 2022; 23: 54-60","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42534696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tamanna Bahar, Shaila Rahman, Zulfia Zinat Chowdhury, T. Kabir, Fahmida Akther, Salina Haque, A. Islam, M. Ali, Md. Mahbubur Rahman
Objective: Febrile neutropenia (FN) is viewed as the most decimating oncological crisis particularly inchemotherapy-incited patients. The primary objective of the study was to identify the total directexpenditure of patients during febrile neutropenia with clinical consequences and the secondary aim wasto find out the factors associated with higher cost. Materials and Method: This was a single-centered hospital-based study in the largest and only specializedcancer care centre in Bangladesh in the government sector. This prospective study was done in theinpatients’ department of the National Institute of Cancer Research and Hospital from April 2020 toJanuary 2021. The primary outcome was the out-of-pocket patient payments (adjusted by governmentsubsidy) per FN episode. Univariate analysis and multiple linear regression were conducted to identifythe factors associated with higher costs. Results and Discussions: A total of 101 patients were enrolled in the study. The mean (SD) age was33.49 (±15.79) years. Of the 101 participants, 63.4% were male. Among the patients, 13.9% died during theepisode and 86.1% recovered. Having co-morbidities and COVID-19 were associated with an increasedrisk of death. The mean cost was US$ 999.44 (±499.05) and the mean length of hospital stay was 21.98(±9.3) days. The longer hospital stay was significantly associated with higher costs. Conclusion: This study will help to ascertain the hospital cost and clinical outcome of FN whichultimately can help in policymaking strategy. J MEDICINE 2022; 23: 48-53
{"title":"Clinical Consequences and Economic Burden Associated with Febrile Neutropenia in Hospitalized Cancer Patients: A Prospective Study","authors":"Tamanna Bahar, Shaila Rahman, Zulfia Zinat Chowdhury, T. Kabir, Fahmida Akther, Salina Haque, A. Islam, M. Ali, Md. Mahbubur Rahman","doi":"10.3329/jom.v23i1.57937","DOIUrl":"https://doi.org/10.3329/jom.v23i1.57937","url":null,"abstract":"Objective: Febrile neutropenia (FN) is viewed as the most decimating oncological crisis particularly inchemotherapy-incited patients. The primary objective of the study was to identify the total directexpenditure of patients during febrile neutropenia with clinical consequences and the secondary aim wasto find out the factors associated with higher cost.\u0000Materials and Method: This was a single-centered hospital-based study in the largest and only specializedcancer care centre in Bangladesh in the government sector. This prospective study was done in theinpatients’ department of the National Institute of Cancer Research and Hospital from April 2020 toJanuary 2021. The primary outcome was the out-of-pocket patient payments (adjusted by governmentsubsidy) per FN episode. Univariate analysis and multiple linear regression were conducted to identifythe factors associated with higher costs.\u0000Results and Discussions: A total of 101 patients were enrolled in the study. The mean (SD) age was33.49 (±15.79) years. Of the 101 participants, 63.4% were male. Among the patients, 13.9% died during theepisode and 86.1% recovered. Having co-morbidities and COVID-19 were associated with an increasedrisk of death. The mean cost was US$ 999.44 (±499.05) and the mean length of hospital stay was 21.98(±9.3) days. The longer hospital stay was significantly associated with higher costs.\u0000Conclusion: This study will help to ascertain the hospital cost and clinical outcome of FN whichultimately can help in policymaking strategy.\u0000J MEDICINE 2022; 23: 48-53","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48341683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MS Alam, M. Rahman, A. Kabir, Md. Uzzwal Mallik, Saima Azad
Background: Acute pancreatitis (AP) is a significant cause of acute abdominal pain, morbidity andhospitalization. Knowing the details of the clinico-pathological presentation and outcome of the diseasemay aid the better understanding of the disease.Objective: The study was designed to assess the clinico-pathological profile and to estimate immediatehospital outcome of acute pancreatitis patients admitted into a tertiary care hospital. Materials and Methods: This hospital based cross-sectional type of observational study was conductedat Dhaka Medical College Hospital (DMCH), for one-year period (June 2018-May 2019).Total 106established cases of acute pancreatitis were included in this study. Data was analyzed by the SPSS 22Windows version and graph & chart were expressed by using SPSS 22 and MS Excel. The Result waspresented with tables and charts. Results: Among 106 patients, mean age of the patients was 42.5 ±11.3 SD (years), with male predominance(male: female-1.2:1). All of the patients complained abdominal pain (100%) while anorexia (48.1%), 43.4%had vomiting and 31.1% had fever. Regarding clinical signs, abdominal distension (45.3%), paralytic ileus(34.9%) and dehydration (43.4%) were found to be the major clinical signs. The common location of painwas in epigastric region (73.6%) with radiation to back in 20.8% patients. Pain was severe agonizing innature in 76.4% cases. Of all, gall stone disease (17.0%) was the most prevalent cause. According toAPACHE-II score, 74.5% patients had mild pancreatitis (APACHE-II <8) while according to Glasgowcriteria, 66.0% had mild disease (Glasgow score <3). Mean APACHE-II score was 7.07±2.50 and Glasgowscore was 2.90±2.33. Mean hospital stays were 8.9±3.6 days and NPO (nothing per oral) 4.9±1.9 days.Among the patients, 77.4% patients were alive and mortality rate was 22.6%. Conclusion: Although, a larger portion of the patients had no identifiable cause but gall stone was themost common etiology. Pain commonly located in epigastric region with radiation to back. Of all thecases, more than sixty percent of the patients had mild pancreatitis estimated by APACHE II score andGlasgow score. Mean hospital stays were about 9 days and nothing per oral was about 5 days. Overallmortality rate was 22.6%. J MEDICINE 2022; 23: 24-29
{"title":"Clinico-pathological Profile and Immediate Hospital Outcome of Acute Pancreatitis","authors":"MS Alam, M. Rahman, A. Kabir, Md. Uzzwal Mallik, Saima Azad","doi":"10.3329/jom.v23i1.57933","DOIUrl":"https://doi.org/10.3329/jom.v23i1.57933","url":null,"abstract":"Background: Acute pancreatitis (AP) is a significant cause of acute abdominal pain, morbidity andhospitalization. Knowing the details of the clinico-pathological presentation and outcome of the diseasemay aid the better understanding of the disease.Objective: The study was designed to assess the clinico-pathological profile and to estimate immediatehospital outcome of acute pancreatitis patients admitted into a tertiary care hospital.\u0000Materials and Methods: This hospital based cross-sectional type of observational study was conductedat Dhaka Medical College Hospital (DMCH), for one-year period (June 2018-May 2019).Total 106established cases of acute pancreatitis were included in this study. Data was analyzed by the SPSS 22Windows version and graph & chart were expressed by using SPSS 22 and MS Excel. The Result waspresented with tables and charts.\u0000Results: Among 106 patients, mean age of the patients was 42.5 ±11.3 SD (years), with male predominance(male: female-1.2:1). All of the patients complained abdominal pain (100%) while anorexia (48.1%), 43.4%had vomiting and 31.1% had fever. Regarding clinical signs, abdominal distension (45.3%), paralytic ileus(34.9%) and dehydration (43.4%) were found to be the major clinical signs. The common location of painwas in epigastric region (73.6%) with radiation to back in 20.8% patients. Pain was severe agonizing innature in 76.4% cases. Of all, gall stone disease (17.0%) was the most prevalent cause. According toAPACHE-II score, 74.5% patients had mild pancreatitis (APACHE-II <8) while according to Glasgowcriteria, 66.0% had mild disease (Glasgow score <3). Mean APACHE-II score was 7.07±2.50 and Glasgowscore was 2.90±2.33. Mean hospital stays were 8.9±3.6 days and NPO (nothing per oral) 4.9±1.9 days.Among the patients, 77.4% patients were alive and mortality rate was 22.6%.\u0000Conclusion: Although, a larger portion of the patients had no identifiable cause but gall stone was themost common etiology. Pain commonly located in epigastric region with radiation to back. Of all thecases, more than sixty percent of the patients had mild pancreatitis estimated by APACHE II score andGlasgow score. Mean hospital stays were about 9 days and nothing per oral was about 5 days. Overallmortality rate was 22.6%.\u0000J MEDICINE 2022; 23: 24-29","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44264731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evidence Based Management of COVID-19 - Bangladesh Perspective","authors":"M. Kabir","doi":"10.3329/jom.v23i1.57929","DOIUrl":"https://doi.org/10.3329/jom.v23i1.57929","url":null,"abstract":"Abstract not available\u0000J MEDICINE 2022; 23: 1-2","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43099067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Saha, S. Nazneen, A. Ahsan, Madhurima Saha, K. Fatema, F. Ahmed, R. Sultana
Background: Central venous catheter (CVC) is usually inserted into subclavian, internal jugular, orfemoral vein in critically ill patients. CVCs are associated with intravascular (infectious, thrombotic) andmechanical complications. CVC related deep venous thrombosis (DVT) is a common intravascularcomplication.Objectives: To see the variation in occurrence of CVC related deep venous thrombosis according todifferent insertion site. Method: It was a prospective observational study conducted in dept. of Critical Care Medicine, BIRDEMGeneral Hospital; during a period of May, 2016 to July, 2019. Purposive sampling was conducted in patientsfulfilling the selection criteria. The CVCs were percutaneously inserted using the Seldinger techniquewith standard operating procedure. After CVC insertion, patients were followed up daily to see any signof deep venous thrombosis. After catheter removal [due to any cause including suspected catheterrelated blood stream infection (CRBSI), DVT, mechanical cause], all the study patients were investigated byduplex ultrasonography (USG) within 2 days for detection of venous thrombosis. The outcome wascatheter related deep venous thrombosis (DVT). Results: A total 349 patients, of which 167 (47.9%) patients had CVC in subclavian, 88 (25.2%) in internaljugular and 94 (26.9%) in femoral vein. Total 12 patients were suspected to have catheter related DVT, but11(3.2%) patients were confirmed as DVT by duplex USG. DVT occurred significantly higher in femoralcatheter site (8.5%) than subclavian (1.8%) and internal jugular site (0%). Conclusion: The occurrence of catheter related DVT was higher in femoral site than other two sites. J MEDICINE 2022; 23: 20-23
{"title":"Comparison of Central Venous Catheter Related Deep Venous Thrombosis According to Insertion Site in an Intensive Care Unit of Bangladesh","authors":"D. Saha, S. Nazneen, A. Ahsan, Madhurima Saha, K. Fatema, F. Ahmed, R. Sultana","doi":"10.3329/jom.v23i1.57932","DOIUrl":"https://doi.org/10.3329/jom.v23i1.57932","url":null,"abstract":"Background: Central venous catheter (CVC) is usually inserted into subclavian, internal jugular, orfemoral vein in critically ill patients. CVCs are associated with intravascular (infectious, thrombotic) andmechanical complications. CVC related deep venous thrombosis (DVT) is a common intravascularcomplication.Objectives: To see the variation in occurrence of CVC related deep venous thrombosis according todifferent insertion site.\u0000Method: It was a prospective observational study conducted in dept. of Critical Care Medicine, BIRDEMGeneral Hospital; during a period of May, 2016 to July, 2019. Purposive sampling was conducted in patientsfulfilling the selection criteria. The CVCs were percutaneously inserted using the Seldinger techniquewith standard operating procedure. After CVC insertion, patients were followed up daily to see any signof deep venous thrombosis. After catheter removal [due to any cause including suspected catheterrelated blood stream infection (CRBSI), DVT, mechanical cause], all the study patients were investigated byduplex ultrasonography (USG) within 2 days for detection of venous thrombosis. The outcome wascatheter related deep venous thrombosis (DVT).\u0000Results: A total 349 patients, of which 167 (47.9%) patients had CVC in subclavian, 88 (25.2%) in internaljugular and 94 (26.9%) in femoral vein. Total 12 patients were suspected to have catheter related DVT, but11(3.2%) patients were confirmed as DVT by duplex USG. DVT occurred significantly higher in femoralcatheter site (8.5%) than subclavian (1.8%) and internal jugular site (0%).\u0000Conclusion: The occurrence of catheter related DVT was higher in femoral site than other two sites.\u0000J MEDICINE 2022; 23: 20-23","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45883902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The increase in mortality and morbidity related to the novel COVID-19 virus led researchers to work ondeveloping new therapies to destroy the virus. Numerous clinical trials have started to find drugs that willeffectively treat the signs and symptoms of the virus. This review aims to summarize the pharmacogenomicaspects of drugs such as hydroxychloroquine, chloroquine, azithromycin, remdesivir, favipiravir, ribavirin,lopinavir/ritonavir, darunavir/cobicistat, interferon beta-1b, tocilizumab, ruxolitinib, baricitinib, andcorticosteroids used in the treatment of this virus. The data will be collected from various websites such asPubMed, Lancet, WHO website, PharmGKB website, IDSA Guidelines on the treatment & management ofCOVID-19 Patients, the U.S. Food and Drug Administration (FDA) product labeling, and pharmacogenomicstables. Incomplete data exists related to the efficacy and safety of these drugs and healthcare providers arestruggling to make the right treatment choices. Drug-gene variants may alter the pharmacokinetics andsafety of some drugs and thus produce adverse drug reactions. Therefore, pharmacogenomics may helpdoctors decide the correct course of treatment by knowing the genetic makeup of an individual. This caneventually help to eliminate adverse drug reactions and reduce the mortality rate. J MEDICINE 2022; 23: 61-76
{"title":"The Pharmacogenomics Aspects of Drugs Used in COVID-19 Treatment","authors":"G. Khan, Yomna Elsayed, M. Said","doi":"10.3329/jom.v23i1.57939","DOIUrl":"https://doi.org/10.3329/jom.v23i1.57939","url":null,"abstract":"The increase in mortality and morbidity related to the novel COVID-19 virus led researchers to work ondeveloping new therapies to destroy the virus. Numerous clinical trials have started to find drugs that willeffectively treat the signs and symptoms of the virus. This review aims to summarize the pharmacogenomicaspects of drugs such as hydroxychloroquine, chloroquine, azithromycin, remdesivir, favipiravir, ribavirin,lopinavir/ritonavir, darunavir/cobicistat, interferon beta-1b, tocilizumab, ruxolitinib, baricitinib, andcorticosteroids used in the treatment of this virus. The data will be collected from various websites such asPubMed, Lancet, WHO website, PharmGKB website, IDSA Guidelines on the treatment & management ofCOVID-19 Patients, the U.S. Food and Drug Administration (FDA) product labeling, and pharmacogenomicstables. Incomplete data exists related to the efficacy and safety of these drugs and healthcare providers arestruggling to make the right treatment choices. Drug-gene variants may alter the pharmacokinetics andsafety of some drugs and thus produce adverse drug reactions. Therefore, pharmacogenomics may helpdoctors decide the correct course of treatment by knowing the genetic makeup of an individual. This caneventually help to eliminate adverse drug reactions and reduce the mortality rate.\u0000J MEDICINE 2022; 23: 61-76","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45074602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-27DOI: 10.20944/preprints202112.0426.v1
Kazi Mahmuda Akter, B. Umar, S. Rahman
Background/Aims: Screening for gestational diabetes mellitus (GDM) are currently done at 24 - 28 weeks of conception, missing out on the most vulnerable period of organogenesis and thus preventing clinicians from starting treatments until the late second or third trimester. MicroRNAs (miR) are small non-coding RNA molecules that could aid in detecting or predicting GDM through establishing a novel non-invasive prenatal testing (NIPT) tool. The objective of this study was to summarize the most recent updates on plasma microRNAs as GDM diagnostic biomarkers. Methods: Between April and June 2021, a PubMed literature search was undertaken to review recent articles on human plasma miR associated with GDM. Animal studies and papers that are written in languages other than English were excluded. Only plasma miRNAs were used to avoid coagulation biases. Results: A total of 31 miRNAs were found significantly upregulated in the plasma samples of patients with GDM. It was found mainly during the 2nd or 3rd trimester except for miR-223 and miR-23a that were upregulated at 9 – 11 weeks of gestation. Conclusion: Though extensive prospective cohort studies are required, miR-223 and miR-23a should be considered the most promising to develop a successful NIPT tool because they were found to be upregulated earliest, during the first trimester.
{"title":"Recent Updates on microRNA as Potential Biomarkers for Diagnosis of Gestational Diabetes mellitus","authors":"Kazi Mahmuda Akter, B. Umar, S. Rahman","doi":"10.20944/preprints202112.0426.v1","DOIUrl":"https://doi.org/10.20944/preprints202112.0426.v1","url":null,"abstract":"Background/Aims: Screening for gestational diabetes mellitus (GDM) are currently done at 24 - 28 weeks of conception, missing out on the most vulnerable period of organogenesis and thus preventing clinicians from starting treatments until the late second or third trimester. MicroRNAs (miR) are small non-coding RNA molecules that could aid in detecting or predicting GDM through establishing a novel non-invasive prenatal testing (NIPT) tool. The objective of this study was to summarize the most recent updates on plasma microRNAs as GDM diagnostic biomarkers. Methods: Between April and June 2021, a PubMed literature search was undertaken to review recent articles on human plasma miR associated with GDM. Animal studies and papers that are written in languages other than English were excluded. Only plasma miRNAs were used to avoid coagulation biases. Results: A total of 31 miRNAs were found significantly upregulated in the plasma samples of patients with GDM. It was found mainly during the 2nd or 3rd trimester except for miR-223 and miR-23a that were upregulated at 9 – 11 weeks of gestation. Conclusion: Though extensive prospective cohort studies are required, miR-223 and miR-23a should be considered the most promising to develop a successful NIPT tool because they were found to be upregulated earliest, during the first trimester.","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44105338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-13DOI: 10.31082/1728-452X-2020-215-216-5-6-38-52
M. Iskakova, Urnisa Kuvatbaeva, Madina Aukhadiyeva
{"title":"Analysis of the dental health level within the framework of a social project for medical examination and maintenance of orphanages in the Republic of Kazakhstan","authors":"M. Iskakova, Urnisa Kuvatbaeva, Madina Aukhadiyeva","doi":"10.31082/1728-452X-2020-215-216-5-6-38-52","DOIUrl":"https://doi.org/10.31082/1728-452X-2020-215-216-5-6-38-52","url":null,"abstract":"","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":"1 1","pages":"38-52"},"PeriodicalIF":0.0,"publicationDate":"2021-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45923756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-13DOI: 10.31082/1728-452X-2020-215-216-5-6-63-70
L. Kuanova, Corporate Fund
{"title":"Anxiety disorders in clinical practice - a modern view on the problem of therapy","authors":"L. Kuanova, Corporate Fund","doi":"10.31082/1728-452X-2020-215-216-5-6-63-70","DOIUrl":"https://doi.org/10.31082/1728-452X-2020-215-216-5-6-63-70","url":null,"abstract":"","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":"1 1","pages":"63-70"},"PeriodicalIF":0.0,"publicationDate":"2021-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47935501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-13DOI: 10.31082/1728-452X-2020-215-216-5-6-53-62
N. Raspopova, Maria Dzhamantayeva, Yerbol Nurkatov, Laila Uteniyazova, Gulnaziya Idenova, Yulia Kotsaba, G. Kozhakhmetova
{"title":"Modern approaches to the diagnosis and treatment of mixed anxiety-depressive disorders in primary health care","authors":"N. Raspopova, Maria Dzhamantayeva, Yerbol Nurkatov, Laila Uteniyazova, Gulnaziya Idenova, Yulia Kotsaba, G. Kozhakhmetova","doi":"10.31082/1728-452X-2020-215-216-5-6-53-62","DOIUrl":"https://doi.org/10.31082/1728-452X-2020-215-216-5-6-53-62","url":null,"abstract":"","PeriodicalId":76013,"journal":{"name":"Journal of medicine","volume":"1 1","pages":"53-62"},"PeriodicalIF":0.0,"publicationDate":"2021-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48813314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：